Qiagen (QGEN) reported $483.46 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.4%. EPS of $0.55 for the same period compares to $0.47 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $464.04 million, representing a surprise of +4.18%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $0.50.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales by Product Groups- Diagnostic solutions- QuantiFERON: $116 million versus $111.16 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +14.9% change.
- Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $34 million versus the four-analyst average estimate of $30.15 million. The reported number represents a year-over-year change of +36%.
- Sales by Product Groups- Other: $18 million versus the three-analyst average estimate of $10.95 million. The reported number represents a year-over-year change of +63.6%.
- Sales by Product Groups- PCR / Nucleic acid amplification: $76 million versus $67.64 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.8% change.
- Sales by Product Groups- Genomics / NGS: $53 million compared to the $54.60 million average estimate based on three analysts. The reported number represents a change of -3.6% year over year.
- Sales by Product Groups- Diagnostic solutions: $187 million versus the three-analyst average estimate of $180.35 million. The reported number represents a year-over-year change of +10%.
- Sales by Product Groups- Sample technologies: $150 million compared to the $150.54 million average estimate based on three analysts. The reported number represents a change of -3.2% year over year.
- Sales by Product Groups- Diagnostic solutions- NeuMoDx: $6 million versus $4.60 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -33.3% change.
- Sales by Product Groups- Diagnostic solutions- Other: $31 million versus $34.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -11.4% change.
View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned +8.7% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
